Use of Palivizumab for Prevention of Hospitalization as a Result of Respiratory Syncytial Virus in Infants With Cystic Fibrosis
| Autor: | Michael E. Speer, Caraciolo J. Fernandes, Marnie L. Boron, Jessie R. Groothuis |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Microbiology (medical) Palivizumab Pediatrics medicine.medical_specialty Cystic Fibrosis Respiratory Syncytial Virus Infections Antibodies Monoclonal Humanized Antiviral Agents Chemoprevention Cystic fibrosis Pneumovirinae Lower respiratory tract infection medicine Humans Mononegavirales biology business.industry Respiratory disease Infant Newborn Antibodies Monoclonal Infant Pneumovirus medicine.disease biology.organism_classification Hospitalization Infectious Diseases medicine.anatomical_structure Pediatrics Perinatology and Child Health Immunology Female business medicine.drug Respiratory tract |
| Zdroj: | Pediatric Infectious Disease Journal. 27:559-561 |
| ISSN: | 0891-3668 |
| DOI: | 10.1097/inf.0b013e3181673c15 |
| Popis: | The Palivizumab Outcomes Registry collected data on 19,548 high-risk infants who received > or =1 dose of palivizumab and followed prospectively from 2000 through 2004. Ninety-one children with cystic fibrosis (CF) were identified who received palivizumab off label. None of the infants with CF who received prophylaxis was hospitalized as a result of respiratory syncytial virus lower respiratory tract infection. Evaluations of palivizumab use in infants with CF could be warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|